Skip to content

Press Releases

Updates on ProBioGen and cover currently relevant topics on human biopharmaceuticals, notably on therapeutic proteins and viral vaccines. 

ProBioGen Teams Up with Granite Bio for Cell Line Development and GMP Manufacturing Services

Berlin, Germany, July 12, 2022 Granite Bio, a Swiss biotech company built through Versant Venture's discovery engine Ridgeline Discovery, and ProBioGen announced the closure of a..

Read More

ValenzaBio Engages ProBioGen For a Second Service Project

Berlin, Germany and Bethesda, MD, USA, June 14, 2022 ProBioGen and ValenzaBio jointly announce today that they have entered into a second service agreement. The new project is a..

Read More

ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®

Berlin, Germany and Bethesda, MD, USA, June 14, 2022 ProBioGen and ValenzaBio jointly announce today that they have entered into a second service agreement. The new project is a..

Read More

ProBioGen Grows by 50 Percent in Last Two Years

Susanne Kaestner and Thea Boehm Join Biopharma Company’s Team Berlin, Germany - June 2, 2022 The Berlin-based biopharmaceutical enterprise ProBioGen has increased its staff by 50..

Read More

Lutz Hilbrich Appointed as Senator to the Senate of Economy Europe

Berlin, Germany, March 7, 2022 MiGenTra and ProBioGen announce the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to the Senate of Economy..

Read More

ProBioGen and Ceva Santé Animale sign an exclusive license agreement to produce vectorised poultry vaccines using AGE1.CR® production technology

Berlin, Germany, March 7, 2022 MiGenTra and ProBioGen announce the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to the Senate of Economy..

Read More

ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio

Feb 4, 2025

ProBioGen Expands Protein and Viral Manufacturing to Drive Continued Growth

Jan 7, 2025

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Nov 5, 2024

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

May 29, 2024

Change in Management

Apr 30, 2024

ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever

Mar 27, 2024

ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology

Mar 13, 2024

ProBioGen was Granted a New Patent for DirectedLuck® Transposase Technology

Dec 14, 2023

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

Sep 26, 2023

ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT™

May 17, 2023

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform

May 4, 2023

ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients

Apr 12, 2023

ProBioGen Delivers Strong 2022 Performance, Investing for Growth in 2023

Mar 30, 2023

ProBioGen’s Growth Strategy Continues Successfully

Mar 2, 2023

Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III

Jan 26, 2023

Press Contact

probiogen-sarah-wandrey

Sarah Wandrey

Corporate Communications

Phone: +49 (0) 30 3229 35 144
Email: press@probiogen.de

ProBioGen News 

Join our news and always be up-to-date.